PT-141 · adverse-event profile · research use only
PT-141 side effects, as the bremelanotide trials actually reported them.
Most research peptides have no human safety data — PT-141 is an exception. Its molecule, bremelanotide, was studied in large FDA registration trials as the product Vyleesi, so there is a published adverse-event table to reference rather than guess from. This page reproduces that data as a research reference: the gastrointestinal and vasomotor events that dominate (nausea, flushing), the transient cardiovascular signal (a small blood-pressure rise with a matching heart-rate dip), and the one finding that is specific to this compound's melanocortin mechanism — focal skin hyperpigmentation. One honest caveat runs through the whole page: the trial figures come from the subcutaneous auto-injector formulation dosed on demand, not from the intranasal research format, so incidence by any other route is not established. It is a summary of published clinical data, not a human-use protocol or medical advice.
Nausea is the defining adverse event
In the pooled Phase 3 trials nausea was reported by roughly 40% of bremelanotide subjects versus about 1% on placebo — by far the most common event. The published pattern is specific: median onset around one hour after dosing, median duration about two hours, worst after the first dose and declining substantially with later doses (down to a few percent after subsequent doses). Around 13% of subjects used anti-emetic therapy and about 8% discontinued because of it. It is a dose-timed, self-limiting event tied to melanocortin activation, not a cumulative one.
Why it's a single acute window →Flushing and vasomotor events
Flushing was the second most common event at about 20% versus under 1% on placebo, with hot flush (~3%) and headache (~11% vs ~2%) also recurring. These vasomotor effects reflect melanocortin-receptor activity in the vasculature and are generally transient and mild-to-moderate. They are the kind of acute, post-dose effects that separate a melanocortin agonist like PT-141 from the gut-dominated profile of a GLP-class metabolic peptide.
PT-141 vs oxytocin →A transient blood-pressure signal
The trials documented a small, transient rise in blood pressure after dosing — on the order of a 6 mmHg systolic and 3 mmHg diastolic peak within about 24 hours, accompanied by a heart-rate decrease of up to ~5 bpm, with both resolving within roughly 12 hours. Because of this the FDA label contraindicates the drug in uncontrolled hypertension or known cardiovascular disease. It is the single most important safety point in the melanocortin literature and the reason the compound is not treated casually.
Route comparison →Focal hyperpigmentation — the melanocortin-specific effect
The finding unique to this mechanism: focal skin hyperpigmentation. PT-141's active metabolite has activity at the MC1R receptor that controls melanin, so darkening of the skin, face, gingiva and breasts was reported in ~1% of subjects on monthly dosing — and critically, it did not resolve in about half of them after stopping. In a separate study 38% developed focal pigment changes after daily dosing for eight days. Subjects with darker skin were more likely to be affected. This is dose-and-frequency-dependent and the label advises considering discontinuation if it develops.
The MC1R pathway vs MT-2 →Most events cluster on the first dose
Unlike the escalation-clustered profile of metabolic peptides, PT-141's events front-load onto the first exposure and attenuate: nausea incidence was highest with the first dose and fell with repeat dosing. The label reports the majority of events as mild (~31%) to moderate (~40%) and transient. That first-dose pattern is why the research literature treats initial exposure differently from ongoing use.
Dosage reference →Research-use framing
Every figure here describes adverse events observed in the human clinical trials of subcutaneous bremelanotide and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of what any individual would experience, and not as instructions for human use. The intranasal research format has no equivalent published incidence table. PT-141 is supplied by Titan strictly as a research-use-only reagent, not for human or animal consumption. Nothing here is medical advice.
Lab testing & COA workflow →The detail, in plain terms
The adverse-event table, at a glance.
Incidence figures are drawn from the pooled Phase 3 placebo-controlled trials of subcutaneous bremelanotide (the Vyleesi FDA label) and reproduced as a research reference. Rates for any non-subcutaneous route, including the intranasal research format, are not established. Figures are approximate and vary by cohort.
- Nausea
- ~40% vs ~1% placebo; onset ~1h, duration ~2h, worst on first dose, ~13% used anti-emetics, ~8% discontinued.
- Flushing
- ~20% vs <1% placebo; vasomotor, transient, mostly mild-moderate.
- Headache
- ~11% vs ~2% placebo.
- Vomiting
- ~5% vs <1% placebo.
- Injection-site reactions
- ~13% (subcutaneous formulation) vs ~8% placebo — a route-specific event, not applicable to nasal research use.
- Hyperpigmentation
- Focal skin/gingival darkening ~1% monthly (up to 38% with 8-day daily dosing); ~half did not resolve after stopping; more likely in darker skin.
- Cardiovascular
- Transient BP rise (~6/3 mmHg peak ~24h) with HR drop up to ~5 bpm, resolving ~12h; contraindicated in uncontrolled hypertension / CVD.
- Severity
- Majority mild (~31%) to moderate (~40%) and transient.
Questions researchers ask
Before you order.
- What are the most common PT-141 side effects in the research?
- In the pooled Phase 3 trials of subcutaneous bremelanotide, the most common events were nausea (~40% vs ~1% placebo), flushing (~20%), headache (~11%) and vomiting (~5%). Nausea had a median onset around one hour and duration around two hours, was worst on the first dose and declined with repeat dosing. These are human clinical-trial figures reproduced as a research reference, not medical advice.
- Does PT-141 raise blood pressure?
- The trials documented a small transient rise — roughly a 6 mmHg systolic and 3 mmHg diastolic peak within about 24 hours, alongside a heart-rate decrease of up to about 5 bpm, both resolving within roughly 12 hours. Because of this the FDA label contraindicates the drug in people with uncontrolled hypertension or known cardiovascular disease. It is the most important safety point in the melanocortin literature.
- Why can PT-141 cause skin darkening?
- PT-141's active metabolite has activity at MC1R, the melanocortin receptor that regulates melanin production — the same pathway its parent compound melanotan-2 is known for. Focal hyperpigmentation of skin, face, gingiva and breasts was reported in about 1% of subjects on monthly dosing and up to 38% with daily dosing for eight days, was more common in darker skin, and did not resolve in about half of affected subjects. It is dose- and frequency-dependent.
- Do the nasal and injectable forms have the same side-effect rates?
- The published incidence table comes only from the subcutaneous auto-injector product studied in FDA trials. There is no equivalent published adverse-event table for the intranasal research format, so rates by that route are not established. Injection-site reactions in particular are specific to the subcutaneous formulation and would not apply to nasal research use. This page reproduces the documented subcutaneous data as the closest available reference.
- Is PT-141 approved for human use?
- The molecule bremelanotide is FDA-approved as a subcutaneous product for a specific indication, but the research-grade PT-141 Titan supplies is not an approved drug. Titan Peptide Lab provides it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The adverse-event data here is a summary of published clinical research and is not medical or dosing advice.